Leadership

Our Founder

Proven oncology drug developer — 9 FDA-approved products generating >$12 B in annual sales

Alfred Slanetz, PhD, ME

Alfred Slanetz, PhD, ME

"Targeting the mutations that cause cancer with the patient's retrained immune system will redefine cancer treatment."

Yale Brown Genentech bluebird bio National Foundation for Cancer Research

Dr. Slanetz has a 20-year record with
9 FDA approved drugs generating $12B annual revenues 1

Immunotherapies
Use Year FDA Approved
HERCEPTIN® First personalized treatment for breast cancer 1998
ABECMA® First CAR-T therapy on the market: malignant myeloma 2021
ZYNTEGLO® Gene therapy: blood disorder (beta thalassemia) 2022
SKYSONA® Gene therapy: genetic brain disease (ALD) 2022
LYFGENIA® Gene therapy: sickle cell anemia 2023
Antibodies
RITUXAN® AVASTIN® LUCENTIS® XOLAIR®

First to discover T-cell receptor recognition (Science Magazine, 1994)

1 2022 annual sales published by Novartis & Roche

Our Team

Paul Abrams, MD, JD

Executive Director

Executive Director

NIH brand NeoRx brand Yale University brand

Dan Kozin, BS, MBA

SVP Business Operations

SVP Business Operations

RPI Brand MIT Brand Babson Brand Silicon Labs Brand Sun Microsystem Brand Sonus Brand Mc Graw Hill Brand

Alexey Bersenev, MD, PhD

Scientific and Process/Manufacturing Advisor

Scientific and Process/Manufacturing Advisor

University of Pennsylvania Brand Yale University Brand

Sriram Srivatsa, PhD

Sr. Research Scientist

Sr. Research Scientist

University of Pennsylvania Brand

Philip Friedlander, MD, PhD

Scientific and Clinical Advisor

Scientific and Clinical Advisor

Mount Sinai Brand Columbia University Brand Memorial Sloan Kettering Cancer Center Brand

Debra Barngrover, PhD

Scientific, Mfg. and Regulatory Advisor

Scientific, Mfg. and Regulatory Advisor

Biologics Consulting Brand Genzyme Brand Cornell University Brand Massachusetts Institute of Technology Brand

Kunal Bhatia

CFO

CFO

Cowen Brand Credit Suisse Brand